Domperidone (like metoclopramide, a D2 receptor antagonist) is not approved for enhanced lactation in the USA.[9][10] By contrast, Australian guidelines consider domperidone to be the preferred galactagogue when non-pharmacological approaches have proved insufficient.[6] Unlike metoclopramide, domperidone does not cross the blood-brain barrier and does not tend to have adverse effects such as drowsiness or depression.[6]